Philippe Boucheron

Philippe Boucheron has more than twenty years of life science investment experience and currently serves as Deputy Chief of Life Sciences Investment at Bpifrance.

From 1993 to 1996, Philippe worked as an associate at BioCapital LP, one of the largest Canadian venture capital funds focusing on healthcare. In 1997, he joined the mid-cap equity research team at ING Barings Ferri, Paris, which he led until 2000 and where he spent a significant part of his time following French and European listed biotech companies.

In 2000, he co-founded Bioam Funds, dedicated to early-stage life science investments, serving as Investment Manager, then, in 2004, as Managing Partner. After the merger of Bioam with CDC Entreprises in July 2010, Philippe joined the CDC Entreprises life sciences team as Investment Manager.

CDC Entreprises, FSI and Oséo merged to create Bpifrance in 2013. Since then, Philippe has served as Deputy Chief of the Life Sciences Investment Business Unit and sits on the company’s Investment Committee. He also serves on the boards of Ademtech, GamaMabs, NH Theraguix, Limflow and CorWave.

Philippe holds degrees in Biochemical Engineering and Microbial Genetics from the National Institute of Applied Sciences in Toulouse (INSA), an MSc in Biochemical Engineering from Ecole Polytechnique (Montréal, Canada) and an MBA from INSEAD.

André Ulmann, MD, PhD

André Ulmann’s career spans over thirty years in research, the pharmaceutical industry and in medical practice. André serves as an active advisor to Advicenne.

André has been a Director of HRA Pharma, which he founded and managed until 2009 before assuming the presidency. In 1999, HRA Pharma launched Norlevo, better known as the “morning-after pill.” Norlevo is now available in more than fifty countries and has made HRA Pharma a pioneer in emergency contraception. Under André’s leadership, HRA Pharma has become a socially-conscious pharmaceutical company that designs and develops medical products and devices for the treatment of rare diseases and unmet medical needs.

André is a MD, and began his career practicing Nephrology at Hospital Necker (Paris, France).

Catherine Dunand

Catherine holds degrees from Ecole Centrale de Lyon and INSEAD (MBA) and received her non-executive director certification from Sciences Po/IFA.

Catherine Dunand has held several executive roles in the pharmaceutical industry, among them, Head of International Marketing and CEO of International geographical profit centers. Working with companies such as Roussel Uclaf and Hoechst Marion Roussel (now part of Sanofi), or Servier, Catherine also conducted several mergers and acquisitions assignments, and reorganization projects.

She then served as the CEO of several small- and mid-cap corporations, leading two successive leveraged buyouts.

Catherine Dunand then dedicated herself to strategy and governance consulting and non-executive assignments for family-owned companies, listed companies and private equity funds.

In 2016 Catherine Dunand co-founded Cemag Invest, a family office investing in healthcare and technology SMEs, she serves as the company’s CEO.

Since 2019 Catherine has been the president of SFFP, a US foundation dedicated to women’s’ health, and since 2020 chairman of the board of Diabeloop SA.

Since 2017 Catherine has been the president of Advicenne’s audit committee and a member of the remco.

Charlotte Sibley

Charlotte Sibley’s career in the healthcare industry spans over forty years, and includes contributing her expertise in market research at Pfizer, and in the medical device sector at Johnson & Johnson. Over the course of her career, Charlotte has also expanded her expertise to the areas of global pharma at Bristol-Myers Squibb and Pharmacia (now Pfizer), biotech at Millennium Pharmaceuticals (now Takeda Oncology), and consumer products at Lipton. She established the US operations for a leading UK-based market research company, achieving profitability in eighteen months in a highly competitive environment. Charlotte also worked as a security analyst for the pharmaceutical industry at Donaldson, Lufkin & Jenrette in New York.

Charlotte was named 2008 Woman of the Year by the Healthcare Businesswomen’s Association in recognition of her leadership, business expertise and mentoring. She was also among those named in PharmaVoice’s Most Inspiring People in Pharma in 2006. She serves on the Boards of Directors of Fort Hill Company, and previously served on the board of Taconic Biosciences, Inc. until it was sold in 2018. Through 2014 she was a member of the Board of American Pacific Corporation (NASDAQ: AMPAC), a leading custom manufacturer of pharmaceutical ingredients and propulsion products.

Charlotte holds an MBA in Finance and Marketing from the University of Chicago Booth Graduate School of Business, and is a National Association of Corporate Directors (NACD) Board Leadership Fellow and Governance Fellow.

Hege Hellstrom

Hege Hellstrom has been a member of the Board of Directors of Advicenne as an independent director since May 2020. She has over 30 years of experience in the medical device, pharmaceutical and biotech industry. She is founder and partner of an investment and consultancy company, Belnor bvba and serves currently as a non-Executive Board member in Oasmia AB (OASM.ST) and Camurus AB (CAMX.ST), both Swedish biotech companies. She is also a board member of Jane Goodall Institute Belgium.

From 2013 to 2018, she was President of Sobi, a Swedish biotech company specialized in rare, genetic diseases such as Haemophilia and metabolic disorders. She orchestrated several successful country launches of products such as Elocta® and Alprolix®, products treating Haemophilia patients.

Prior to Sobi, Hege worked 11 years in Genzyme, a Boston based company where she was Head of the Renal and Endocrine Business Unit for Europe, JAPAC and Latin-America, as well as General Manager for Benelux. When Sanofi acquired Genzyme, she became Global Head of the Cardiovascular Unit of Sanofi.

From 1989 to 2002, Hege worked at Baxter in Norway and Belgium. During her career she has had commercial experience from pre-launch and launch, to end of lifecycle management of a wide range of products in many disease areas.

Hege has a B.Sc as a Medical Laboratory Scientist from Oslo Metropolitan University, Norway and has completed an Executive Board programme at INSEAD.

Jean-Michel Petit

Jean-Michel Petit is a Director at IRDI Capital Investment, where he manages the seed fund IRDInov, investing in start-ups located in the southwest of France. He serves on the boards of several portfolio companies such as Gamamabs, Ademtech, Exotrail, Solvionic, Azur Light technologies, SmartCatch and Micropep. Before joining IRDI, Jean-Michel spent four years at CDP Capital as part of the Life Sciences venture capital team, based initially in Montréal and then in Paris, where he made a range of international investments (mostly in the US). Prior to CDP Capital, he worked for a regional fund based in Montréal, Canada.

Jean-Michel graduated from Chimie ParisTech and holds an M.Sc. from Montréal University, as well as an MBA from McGill University (Montréal, Canada).

Thibaut Roulon, PhD

Thibaut started his career as a scientist in a US biotech company developing cancer immunotherapeutics.

In 2005 he joined Bioam Gestion, a venture capital firm investing in life science companies. In 2010, Bioam merged with Bpifrance, a leading French investment firm investing in SMEs and mid-Tier companies. Bpifrance manages several funds dedicated to life science investments, including InnoBio and InnoBio 2.

Thibaut is in charge of investments in life sciences companies at various stages (Seed, Venture, IPO, PIPE).

He is a graduate of the Ecole Centrale de Paris and holds a PhD from the Pierre & Marie Curie University.